Shilpa Medicare excludes FTF Pharma after September 9 CIRP

Shilpa Medicare Limited stopped consolidating FTF Pharma Private Limited after September 8, 2026, because the September 9 Corporate Insolvency Resolution Process transferred management and control to an Interim Resolution Professional, lowering reported September-quarter profit before tax, or PBT, by Rs 3.75 crore versus full-quarter inclusion. The National Company Law Appellate Tribunal has reserved judgment on Shilpa Medicare’s appeal.

What happened to FTF Pharma Private Limited on September 9, 2026?

The National Company Law Tribunal, Ahmedabad Bench, initiated the Corporate Insolvency Resolution Process, or CIRP, against FTF Pharma on September 9, 2026, after an operational creditor filed a petition. The auditor identified FTF Pharma as a wholly owned subsidiary and said an Interim Resolution Professional, or IRP, was appointed under the Insolvency and Bankruptcy Code, 2016.

The immediate consequence was that FTF Pharma’s management and control vested in the IRP from September 9, 2026. Shilpa Medicare therefore included the subsidiary’s financial results only through September 8, the day before CIRP began, in the unaudited consolidated results for the quarter and six months ended September 30, 2026.

The filing does not identify the operational creditor or state the amount of its claim. Shilpa Medicare said its challenge to the September 9 order rests on its contention that the proceedings were initiated on the basis of a disputed claim, leaving the legal outcome unresolved as of the November 5, 2026 results announcement.

Why did Shilpa Medicare stop consolidating FTF Pharma?

Shilpa Medicare stopped consolidation because Indian Accounting Standard 110, or Ind AS 110, links consolidated reporting to control, which passed to the IRP when CIRP commenced on September 9, 2026. The accounting cut-off was consequently September 8 rather than the September 30 quarter-end.

This treatment excludes FTF Pharma’s results for September 9 to September 30, 2026 from the Group’s unaudited consolidated financial results. The disclosure does not describe a sale of FTF Pharma or a disposal of Shilpa Medicare’s ownership interest; it attributes the reporting change to CIRP and the vesting of management and control in the IRP.

The independent auditor made the matter an emphasis-of-matter item in its November 5, 2026 review report. The auditor nevertheless said its conclusion was not modified, meaning it drew attention to the consolidation cut-off without changing its review conclusion on the September 30, 2026 consolidated results.

How much did FTF Pharma’s exclusion affect quarterly results?

FTF Pharma’s exclusion lowered reported consolidated revenue by Rs 2.78 crore, earnings before interest, depreciation and amortisation, or EBITDA, by Rs 4.32 crore, and PBT by Rs 3.75 crore for the quarter ended September 30, 2026, according to Shilpa Medicare. Those measures would have been higher by the stated amounts if the subsidiary had remained consolidated for the full quarter.

The company’s results note gives the revenue and PBT effects as Rs 2.78 crore and Rs 3.75 crore, respectively. The auditor’s November 5 review report gives revenue lower by Rs 2.7762 crore and PBT lower by Rs 3.7532 crore, while not stating an EBITDA figure in its emphasis-of-matter paragraph.

The disclosure does not provide a line-by-line reconciliation of FTF Pharma’s revenue and costs for September 9 to September 30, 2026. It therefore establishes the impact on consolidated revenue, EBITDA and PBT, but not the underlying period’s individual expense categories or cash-flow effect.

What is the status of Shilpa Medicare’s NCLAT appeal?

Shilpa Medicare’s appeal remains pending because the National Company Law Appellate Tribunal, or NCLAT, reserved its judgment on October 8, 2026. The NCLAT also directed the IRP not to conduct any further proceedings until judgment is pronounced, according to the November 5 filing.

Management said it was confident of a favourable outcome based on the facts and circumstances, submissions before the NCLAT and legal advice obtained. That is management’s view rather than a court decision, and the filing gives neither a date for the judgment nor a quantified effect of a potential outcome on future consolidation.

The September 2026 results also contain a separate prior-period comparability change related to the merger of Shilpa Therapeutics Private Limited with Shilpa Medicare. The NCLT Bengaluru Bench sanctioned that merger on February 27, 2026 with an appointed date of April 1, 2025, and the company restated standalone September 2025 figures using the pooling-of-interests method.

For the quarter ended September 30, 2025, restated standalone total income was Rs 147.59 crore, compared with Rs 151.88 crore previously published. Restated standalone PBT was Rs 36.32 crore, compared with Rs 38.92 crore previously published, while total comprehensive income was restated to Rs 29.19 crore from Rs 30.83 crore.

Conclusion

The CIRP created an immediate reporting change for Shilpa Medicare: FTF Pharma was consolidated only through September 8, 2026, rather than through the September 30 quarter-end. Compared with full-quarter consolidation, the company disclosed lower September-quarter consolidated revenue of Rs 2.78 crore, lower EBITDA of Rs 4.32 crore and lower PBT of Rs 3.75 crore, while the auditor retained an unmodified review conclusion.

The next disclosed event is the NCLAT judgment, which was reserved on October 8, 2026 after the tribunal directed the IRP not to take further action pending its decision. Management has expressed confidence in a favourable outcome, but Shilpa Medicare did not disclose a judgment timetable or the prospective accounting treatment should the appeal be decided in its favour.